A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom’s macroglobulinemia (PCYC-1127-CA).

Meletios A. Dimopoulos; Xavier Leleu; Jeffrey Matous; David MacDonald; Judith Trotman; Albert Oriol; Chaim Shustik; Alessandra Tedeschi; Ramon Garcia-Sanz; Leonard T. Heffner; Shuo Ma; Beatrice Mahe; Constantine Tam; Olivier Tournilhac; Jianling Li; Priyanka Singh; Elizabeth Bilotti; Thorsten Graef; Steven P. Treon; Christian Buske

doi:10.1200/JCO.2015.33.15_SUPPL.TPS8599

A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom’s macroglobulinemia (PCYC-1127-CA).

Meletios A. Dimopoulos
, Xavier Leleu
, Jeffrey Matous
, David MacDonald
, Judith Trotman
, Albert Oriol
, Chaim Shustik
, Alessandra Tedeschi
, Ramon Garcia-Sanz
, Leonard T. Heffner
, Shuo Ma
, Beatrice Mahe
, Constantine Tam
, Olivier Tournilhac
, Jianling Li
, Priyanka Singh
, Elizabeth Bilotti
, Thorsten Graef
, Steven P. Treon
, Christian Buske

National and Kapodistrian University of Athens
Service des Maladies du Sang, Hôpital Claude Huriez, Lille, France
Colorado Blood Cancer Institute, Denver, CO
Dalhousie University
Concord Hospital
Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Barcelona, Spain
Royal Victoria Hospital, Montreal, QC, Canada
Department of Hematology Ospedale Niguarda Ca' Granda, Milano, Italy
Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
Emory University
Northwestern University
Hematology, University Hospital, Nantes, France
Peter MacCallum Cancer Centre
University of Auvergne
Pharmacyclics, Inc., Sunnyvale, CA
Harvard University
University of Ulm

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	33
DOIs	https://doi.org/10.1200/JCO.2015.33.15_SUPPL.TPS8599
State	Published - May 20 2015
Externally published	Yes

Disciplines

Medicine and Health Sciences
Gastroenterology
Surgery
Internal Medicine

Access to Document

10.1200/JCO.2015.33.15_SUPPL.TPS8599License: Unspecified

Cite this

Dimopoulos, M. A., Leleu, X., Matous, J., MacDonald, D., Trotman, J., Oriol, A., Shustik, C., Tedeschi, A., Garcia-Sanz, R., Heffner, L. T., Ma, S., Mahe, B., Tam, C., Tournilhac, O., Li, J., Singh, P., Bilotti, E., Graef, T., Treon, S. P., & Buske, C. (2015). A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom’s macroglobulinemia (PCYC-1127-CA). Journal of Clinical Oncology, 33. https://doi.org/10.1200/JCO.2015.33.15_SUPPL.TPS8599

Dimopoulos, MA, Leleu, X, Matous, J, MacDonald, D, Trotman, J, Oriol, A, Shustik, C, Tedeschi, A, Garcia-Sanz, R, Heffner, LT, Ma, S, Mahe, B, Tam, C, Tournilhac, O, Li, J, Singh, P, Bilotti, E, Graef, T, Treon, SP & Buske, C 2015, 'A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom’s macroglobulinemia (PCYC-1127-CA).', Journal of Clinical Oncology, vol. 33. https://doi.org/10.1200/JCO.2015.33.15_SUPPL.TPS8599

@article{6794c54f9c414a37906744535f4dca24,

title = "A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom{\textquoteright}s macroglobulinemia (PCYC-1127-CA).",

author = "Dimopoulos, \{Meletios A.\} and Xavier Leleu and Jeffrey Matous and David MacDonald and Judith Trotman and Albert Oriol and Chaim Shustik and Alessandra Tedeschi and Ramon Garcia-Sanz and Heffner, \{Leonard T.\} and Shuo Ma and Beatrice Mahe and Constantine Tam and Olivier Tournilhac and Jianling Li and Priyanka Singh and Elizabeth Bilotti and Thorsten Graef and Treon, \{Steven P.\} and Christian Buske",

note = "TPS8599 Background: Current treatments for Waldenstrom's macroglobulinemia (WM) are not curative, and a standard of care does not exist. A highly recurrent somatic mutation in WM, MYD88 L265P, signals through interleukin-1 receptor-associated kinase 1 and Bruton's tyrosine kinase (BTK) to mediate the constitutive activation of the NF-κB pathway (Yang, 2013).",

year = "2015",

month = may,

day = "20",

doi = "10.1200/JCO.2015.33.15\_SUPPL.TPS8599",

language = "American English",

volume = "33",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom’s macroglobulinemia (PCYC-1127-CA).

AU - Dimopoulos, Meletios A.

AU - Leleu, Xavier

AU - Matous, Jeffrey

AU - MacDonald, David

AU - Trotman, Judith

AU - Oriol, Albert

AU - Shustik, Chaim

AU - Tedeschi, Alessandra

AU - Garcia-Sanz, Ramon

AU - Heffner, Leonard T.

AU - Ma, Shuo

AU - Mahe, Beatrice

AU - Tam, Constantine

AU - Tournilhac, Olivier

AU - Li, Jianling

AU - Singh, Priyanka

AU - Bilotti, Elizabeth

AU - Graef, Thorsten

AU - Treon, Steven P.

AU - Buske, Christian

N1 - TPS8599 Background: Current treatments for Waldenstrom's macroglobulinemia (WM) are not curative, and a standard of care does not exist. A highly recurrent somatic mutation in WM, MYD88 L265P, signals through interleukin-1 receptor-associated kinase 1 and Bruton's tyrosine kinase (BTK) to mediate the constitutive activation of the NF-κB pathway (Yang, 2013).

PY - 2015/5/20

Y1 - 2015/5/20

UR - https://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.tps8599

U2 - 10.1200/JCO.2015.33.15_SUPPL.TPS8599

DO - 10.1200/JCO.2015.33.15_SUPPL.TPS8599

M3 - Article

VL - 33

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom’s macroglobulinemia (PCYC-1127-CA).

Disciplines

Access to Document

Other files and links

Cite this